AstraZeneca and Daiichi Sankyo Provide Update on the P-III (TROPION-Breast01) Study of Datopotamab Deruxtecan to Treat Breast Cancer
Shots:
- The P-III (TROPION-Breast01) study assessed datopotamab deruxtecan (6mg/kg) vs CT to treat inoperable or metastatic HR+/HER2-low or -ve breast cancer patients (n=700) progressed on ET & received at least 1 systemic therapy
- Study significantly improved dual 1EP of PFS but was unable to show significant OS, improved patient-reported outcomes were observed. PFS data was highlighted at ESMO 2023, with key 2EPs published in the JCO
- Safety profile aligned with the previous analysis, showing low rates of grade 3 or higher TRAEs without any new safety outcomes, ILD rates stayed low without any new severe events. Data will be highlighted at upcoming conferences & shared with regulators reviewing this indication
Ref: AstraZeneca | Image: AstraZeneca & Daiichi Sankyo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
